reading triple agonist threads from 2024 and half of it aged badly
Something I keep coming back to: reading triple agonist threads from 2024 and half of it aged badly.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
[deleted]
nothing here is available as a prescription product, so read every thread with that in mind
the energy-expenditure story is mechanistically interesting and clinically unproven
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
a lot of the confident posting here is extrapolation
Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.
What do you think the glucagon component is adding, specifically?
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Kept a log specifically because there is so little published. It is one person and it is not data.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
the escalation is where most of the reported trouble sits
research-use-only material is not approved for human use, full stop
phase 2 data only, and people quote it like it is a label
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Are you comparing against phase 3 numbers for something else? They are not comparable.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
How fast was the escalation? That is usually the variable that explains the reports.
Not convinced. You are attributing a week of fatigue to the glucagon arm when the escalation rate alone would explain it.
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
comparing reta phase 2 to sema phase 3 is comparing different things
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
What is the source for that figure — the published paper or a summary of it?
- 1phase 2 data only, and people quote it like it is a label14 comments in this branch · started by u/honest_syringe_2025
- 2It is a triple agonist at the GLP-1, GIP and glucagon receptors. The…6 comments in this branch · started by u/signe_villalobos